South Korea, Seongnam–(business wire)–GI CELL, Inc. today announced that it has entered into a Research License and Option Agreement with Optieum Biotechnologies, Inc. (Japan). Under this agreement, Optieum Biotechnologies will provide his GI CELL with scFv antibodies against hematologic tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will conduct feasibility studies and will be responsible for further development and commercialization of CAR-NK cell products should the company exercise its option. For each option exercised, Optieum Biotechnologies will be entitled to option exercise fees, development and commercial milestone payments, and his single-digit royalties on sales.
“We are delighted to begin this collaboration with Optieum Biotechnologies as we continue to unlock the full potential of our NK.pure Dr. Chun Pyo Hong, CEO of GI CELL said: We look forward to evaluating his scFv antibodies from Optieum Biotechnologies’ discovery platform. This has the potential to accelerate the development of our new His CAR-NK cells. ”
“Through our proprietary Eumbody System™, we have been dedicated to expanding the toolbox that enables immune cell-based therapies in cancer therapy,” said Shun, CEO of Optieum Biotechnologies. Nishioka says:
About GI cells
GI CELL is a biotechnology company driving the research and development of new immune cell-based therapeutics using innovative technologies.Uses unique immune cellspure A highly powerful Expander® platform for NK and T cell development, GI CELL integrates ancillary material screening and cell expansion techniques to streamline the entire cell product development process. The company advances allogeneic NK cell therapy, transforming the treatment paradigm for patients with hematologic malignancies and solid tumors. GI CELL has multiple NK cell product candidates in IND-ready and pre-clinical development.
For more information, please visit https://www.gi-cell.com/en/.
About Optium Biotechnologies
Optieum Biotechnologies is a biotechnology company with a platform engine to derive functional and improved scFvs for CAR-T cell and CAR-NK therapy with superior anti-tumor toxicity and persistence. Optieum Biotechnologies’ scFv generation platform, the Eumbody System, allows us to capture his scFv in terms of CAR-T cell function rather than the traditional binding affinity approach. The company is advancing multiple CAR-T cell product candidates targeting hematologic malignancies and solid tumors that demonstrate significantly improved anti-tumor toxicity, proliferative potential and reduced antigen depletion.
For more information, please visit https://optieumbio.com/.